SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs acknowledged affair with a businesswoman reportedly suspected of ties to Chinese intelligence, and Nvidias board investigation into related concerns, are weighing on shares. Traders disagree on whether the episode threatens leadership and investor confidence or is an overreaction with little impact on Nvidias AI-chip business; dip-buying and bearish calls are both prominent.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs stronger-than-expected Q3 results and raised full-year revenue outlook are driving attention, with traders also pointing to record backlog and demand for its quantum systems. Bulls welcome the growth and commercial momentum, while skeptics question cash burn, acquisition-driven revenue, and dilution.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims Q3 earnings are in focus after a sharp selloff, with traders weighing the impact of its Eli Lilly deal to offer branded obesity drugs on the platform. Bulls see expanded GLP-1 access as a growth opportunity, while skeptics worry the shift from compounded products could pressure margins; claims of leaked results remain speculation.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels positive Phase 3 prostate cancer results and planned CAN-2409 BLA filing are the main focus, with recent SITC immune-profiling and viral-shedding data drawing added attention to the program. Bulls see the data and filing as potential catalysts, while skeptics question the timeline, financing needs and managements transparency.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk shares are surging ahead of its Q3 earnings report, with traders attributing the move to short covering and speculating about a possible earnings leak, though no leak is confirmed. The rally is contentious: some expect a turnaround or squeeze, while others fear the report and outlook will disappoint after weakening growth.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two is drawing attention ahead of its earnings report and the scheduled GTA VI launch, with traders focused on preorder demand, managements outlook and the games potential for ongoing online revenue. Many expect the blockbuster to drive growth, while others argue its success is already priced in and the shares may need concrete sales results to move higher.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Fireflys engine, technology-licensing and engineering agreement with AST SpaceMobile for its planned Blacklift rocket, alongside NASAs CLPS 2 selection, is driving attention. Traders see the deal as validation and a boost to Fireflys backlog, while debating execution, the stock component of the agreement and funding risks ahead of earnings.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is drawing attention ahead of the FDAs decision on deramiocel for Duchenne muscular dystrophy, with traders focused on whether the amended applications HOPE-3 upper-limb data will support approval; the trial investigators support letter is a bullish talking point, while the earlier advisory-panel vote concerned the cardiac indication. Sentiment is largely optimistic, with calls and short-squeeze potential frequently discussed, but traders also acknowledge the binary risk of a rejection or another delay.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs sharp rebound is being linked to Oppenheimers upgrade and Google Clouds use of AMD EPYC processors in its AI infrastructure, while traders also see Nvidias CEO investigation as a reason for money to rotate toward AMD. Bulls view the companys data-center momentum and rival-related headlines as supportive, while skeptics warn the move may be a volatile bounce after the recent semiconductor selloff.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerrys QNX and Valeo collaboration on a production-ready smart-camera platform, with design wins at multiple Chinese automakers, is driving attention. Many traders view it as evidence of expanding QNX adoption in automotive and a growth catalyst, while skeptics question how quickly wins will translate into meaningful revenue.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Agenus BOT+BAL update reporting long-term survival in heavily pretreated MSS metastatic colorectal cancer is driving attention, alongside discussion of the planned Phase 3 ROBBIN trial. Bullish traders see the results as evidence of promise in difficult-to-treat tumors, while skeptics question the small, nonrandomized data and continue to flag execution and dilution risks.

Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down

AGEN's Q3 earnings meet estimates, but a revenue miss weighs on shares as pipeline progress, Armenian drug approvals and new funding emerge as key developments.

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new findings from a long-term survivor analysis of its Phase 1b C-800-01 trial evaluating botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1...

Agenus (AGEN) Q3 Earnings Meet Estimates

Agenus (AGEN) delivered earnings and revenue surprises of 0.00% and -10.03%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the third quarter ended September 30, 2026, and highlighted progress preparing its global randomized Phase 3 ROBBIN trial of botensilimab (BOT), a multifunctional, Fc-enhanced anti-CTLA-4...

Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Chief Commercial Officer, and Zack Armen, Vice President of Corporate Development and Investor Relations, will participate in a virtual fireside chat hosted by Rodman & Renshaw on Thursday...

Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of results from the investigator-sponsored, multicenter Phase 2 UNICORN trial evaluating short-course preoperative, or neoadjuvant, botensilimab (BOT), Agenus multifunctional...

Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced early Phase 2 results from the mismatch repair-deficient (dMMR) colon cancer cohort of NEOASIS, an investigator-initiated pan-tumor study sponsored by the Netherlands Cancer Institute (NKI). NEOASIS is evaluating...

Agenus to Provide Third Quarter 2026 Financial Report and Development Update

Agenus Inc. (Agenus) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026 financial results before the market opens on Thursday, November 5, 2026. The earnings release will review Agenus recent progress in advancing...

Agenus to Participate in Chardans 10th Annual Healthcare Investor Conference

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Zack Armen, Head of Corporate Development and Investor Relations, will participate in a fireside chat and one-on-one investor meetings at Chardans 10th Annual Healthcare Conference: The Next 10 Years of...

Armenia Grants First Marketing Authorizations for Agenus BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Ministry of Health of the Republic of Armenia has granted marketing authorizations for Botvymo (botensilimab, BOT) and Evamplix (balstilimab, BAL), each approved for use in combination with the other for...

This account has been verified as an official AGEN representative.

Verified Account

Agenus Communications

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment

Equity

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>Net proceeds from the financing are slated to fund a late-stage colon cancer clinical trial and potentially provide cash runway through 2031.</li><li>Agenus is also shifting its main drug combination to treat high-risk, earlier-stage colon cancer before surgery.&nbsp;</li><li>The condition represents a potential U.S. market opportunity of more than $7 billion annually, Agenus said.</li></ul><p><br>Agenus (AGEN) shares jumped 100% on Monday after the company announced an oversubscribed private placement of up to $340 million and a strategic pivot to prioritize its lead program in earlier-stage colon cancer.</p><p>The stock is now on track for its best day ever, if gains hold.</p><h2 class="st-heading-2">Financing Details</h2><p>Agenus is raising up to $340 million from investors through a private deal. It expects to receive about $85 million soon, with the potential for another $255 million later if investors buy more shares.</p><p>Net proceeds from the financing are slated to fund a late-stage colon cancer clinical trial and potentially provide cash runway through 2031.</p><p>The company had just $35.0 million in cash and cash equivalents as of March 31.</p><h2 class="st-heading-2">New Pipeline Focus</h2><p>Agenus is shifting its main drug combination (botensilimab plus balstilimab) to treat high-risk earlier-stage colon cancer before surgery, the company said. It now plans a large, late-stage study in the patient population, with the first patient expected to be dosed in the first quarter of 2027. The condition represents a potential U.S. market opportunity of more than $7 billion annually, Agenus said.</p><p>At the same time, Agenus is stopping financial support for a different study in patients with more advanced colon cancer. Earlier, smaller studies of the drug combination showed promising results, with many patients responding well to the treatment, it noted.</p><h2 class="st-heading-2">Expert Takeaway</h2><p>H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on Agenus to $30 from $23 and kept a ‘Buy’ rating on the shares. H.C. Wainwright views the shift in strategy as favorable, saying there is currently no standard of care in neoadjuvant treatment for the condition. The firm’s new price target represents a potential upside of about 796% from the stock’s last closing price.</p><p>On X, the investor commonly referred to as ‘Pharma bro,’ Martin Shkreli wrote, “short $AGEN - PIPE does not change bleak outlook. should trade back to PIPE price.”</p><h2 class="st-heading-2">How Did AGEN Retail Traders React?</h2><p>On Stocktwits, retail sentiment around AGEN stock rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘normal’ to ‘extremely high’ levels.</p><p>A Stocktwits user expressed optimism for the pipeline pivot, increasing the market potential of the company’s drug combination.</p><p><stembedurl>https://www.stocktwits.com/jcilip/message/658917933</stembedurl></p><p>Another user voiced hopes for a further rally.</p><p><stembedurl>https://www.stocktwits.com/M105/message/658921495</stembedurl></p><p>According to data from Koyfin, both the analysts covering AGEN rate it a ‘Buy.’ The 12-month average price target on the stock is $15.50, representing a potential upside of 363% from the stock’s Friday close.</p><p><a href="https://stocktwits.com/symbol/AGEN">AGEN stock</a> has more than doubled year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/kvue-stock-dips-after-court-revives-tylenol-autism-lawsuits/cZmzDliR7Yj">KVUE Stock Dips After Court Revives Tylenol Autism Lawsuits</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Agenus logo is displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Agenus expects to receive about $85 million soon under a placement, with the potential for another $255 million later. 

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	-$0.34	--	--	N/A
Q3 '26	-$0.28	--	--	N/A
Q2 '26	$0.05	--	--	N/A
Q1 '26	$2.10	--	--	N/A
Q4 '25	-$1.04	--	--	N/A

Feed

News

Sentiment

Earnings

Fundamentals

Info

AGEN Earnings

Latest Earnings Results: Q4 '26

Historical Earnings